EAM
BEAM icon

Eventide Asset Management’s Beam Therapeutics BEAM Stock Holding History

Eventide Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-261,360
Closed -$7.11M – 162
2023
Q4 		$7.11M Hold
261,360
– – 0.12% 131
2023
Q3 		$6.29M Sell
261,360
-197,843
-43% -$5.3M 0.11% 133
2023
Q2 		$14.7M Hold
459,203
– – 0.25% 102
2023
Q1 		$14.1M Buy
459,203
+192,178
+72% +$7.58M 0.26% 105
2022
Q4 		$10.4M Hold
267,025
– – 0.21% 103
2022
Q3 		$12.7M Buy
+267,025
New +$15.2M 0.25% 96

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Eventide Asset Management's BEAM Position: Q1 2024 in Review

Eventide Asset Management sold out of Beam Therapeutics (BEAM) in Q1 2024, closing a stake of 261,360 shares — an estimated $7.11M sold.

Eventide Asset Management first reported a position in BEAM in Q3 2022 and held it in 6 quarters. The position peaked at $14.7M in Q2 2023. 221 funds tracked by Wall St. Rank hold BEAM as of Q1 2024.

  • Eventide Asset Management reported no remaining Beam Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Eventide Asset Management sold 261,360 Beam Therapeutics shares in Q1 2024, an estimated $7.11M.
  • Eventide Asset Management first reported a position in Beam Therapeutics in Q3 2022 and held it in 6 quarters.
  • Eventide Asset Management's Beam Therapeutics position peaked at $14.7M in Q2 2023.
  • 221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2024.

Based on Eventide Asset Management's 13F filing for Q1 2024, filed 15 May 2024.